Neko Health Raises $700M to Enter US Market: Spotify Founder's Preventive Medicine Push

Neko Health, the health tech startup co-founded by Spotify founder Daniel Ek, has completed a $700 million (approximately 105 billion yen) funding round from prominent investors and announced its full-scale entry into the US market. According to a report by The Verge on July 15, the company plans to open its first clinic in New York City within the year, followed by rapid expansion across the United States.

Neko Health operates private clinics that offer full-body scans and blood tests, combining AI with proprietary medical hardware. Founded in 2018, the company operated under the radar until 2023. It currently runs a total of eight clinics in the UK and Sweden: four in London and two in Stockholm. Scan prices are set at £299 (about $400) in the UK and 2,750 Swedish kronor (about $285) in Sweden. Pricing for US operations has not been disclosed.

Aiming to Democratize Preventive Medicine

Neko Health’s core technology is an AI-powered full-body scanning system. Specially designed medical hardware screens for diseases such as skin cancer, heart disease, and diabetes at an early stage. The company’s goal is to detect illnesses before symptoms appear, enabling prevention and extending people’s healthy lifespans.

Co-founder and CEO Hjalmar Nilsonne stated in a press release that this funding round is intended to “realize that mission for the first time in the US.” The funds will be used to open clinics in New York and other major US cities, as well as for research and development of technology that Nilsonne describes as enabling “prevention at scale.” The waiting list for the New York location is already open on the company’s website.

Star Investors Join the Round

The funding round features a roster of celebrities, entrepreneurs, and investment firms. New investors include musician will.i.am, tennis player Maria Sharapova, Meta CEO Mark Zuckerberg and his wife Priscilla Chan, and former soccer player Thierry Henry. Details of existing backers have not been disclosed, but Neko Health has previously raised funds in multiple rounds.

This lineup of star investors signals strong interest in Neko Health’s business model and the potential of the preventive medicine market. In particular, Zuckerberg’s participation can be seen as a strategic move into “metaverse” and “digital health” initiatives championed by Meta.

Rising Demand and Scaling Challenges

Neko Health has met strong demand at its existing clinics but also faces challenges associated with scaling. According to the company, over 350,000 people have registered or applied for the scan waiting list, and 100,000 have actually been scanned. This figure clearly demonstrates the high level of consumer interest in preventive medicine.

On the other hand, the eight clinics in the UK and Sweden are struggling to keep up with demand. The company has yet to announce specific locations or detailed timelines for new sites, but the US market entry could be an opportunity to alleviate this supply shortage.

Expansion of the Preventive Medicine Market

and Limitations of Traditional Healthcare

The preventive medicine and private screening market, in which Neko Health operates, has been growing rapidly in recent years. This growth is driven by rising interest in longevity and biohacking, as well as dissatisfaction with traditional healthcare systems that take a “reactive” approach by addressing symptoms after they appear.

Preventive medicine promotes early detection and treatment by offering more detailed and comprehensive scans at lower prices compared to conventional check-ups. For lifestyle-related diseases such as cancer and heart disease, early detection directly impacts treatment outcomes. Startups like Neko Health aim to fill this gap.

Privacy and Regulatory Challenges

Entering the US market, Neko Health faces several challenges. First, there are regulations concerning the handling of medical data. In the US, HIPAA (Health Insurance Portability and Accountability Act) strictly governs the collection, storage, and sharing of patient data, requiring high compliance levels. When the company uses AI to analyze scan data, data privacy protection becomes a critical issue.

Additionally, varying regulations on medical practices across states could pose barriers to nationwide expansion. It has not been announced whether Neko Health will open its own clinics or partner with existing medical institutions, but it must obtain appropriate licenses and approvals in each market.

Furthermore, whether the company’s scanning technology requires FDA (U.S. Food and Drug Administration) approval is a key decision point. AI diagnostic support systems are often regulated as medical devices. Entering the market without prior FDA approval could create legal risks.

Differentiation Strategy Against Competitors

In the preventive medicine field, several competitors exist in the US. For example, Forward Health, One Medical, and Parsley Health offer private primary care and preventive services. Companies specializing in blood tests like Thrive, genetic testing like 23andMe, and imaging like Prenuvo are also potential competitors.

Neko Health’s strength lies in its integrated solution combining proprietary hardware and AI to offer low-cost full-body scans. Based on its track record in the UK and Sweden, the company’s strategy is to differentiate itself from competitors through a balance of pricing and service quality. However, in the US market, where healthcare costs are high, pricing will be key to customer acquisition.

Editorial Opinion

In the short term, Neko Health’s entry into the US is likely to have a significant impact on the preventive medicine market. The first clinic opening in New York within the year will serve as a litmus test for the company’s service quality and US market demand. With many consumers dissatisfied with the traditional healthcare system, Neko Health’s ability to offer detailed full-body scans at a low price could help it capture a certain customer base. However, pricing and insurance coverage will be critical to widespread adoption.

In the long term, the growth of the preventive medicine market could drive structural transformation of the entire healthcare system. If the shift from the traditional “treat after symptoms appear” model to a “detect risks early and prevent” model accelerates, it could lead to reduced healthcare costs and extended healthy lifespans. On the other hand, AI-powered health scans carry risks of privacy infringement and data misuse, making societal debate essential. Until a regulatory framework is established, voluntary governance by private companies will be put to the test.

The editorial team questions whether preventive medicine could exacerbate health inequality.

References

• “Spotify’s Daniel Ek is bringing his body-scanning clinics to the US”, by Robert Hart — The Verge, 2026-07-15T10:13:47.000Z (ARR)
• Source URL: https://www.theverge.com/science/965849/spotify-founder-ek-startup-neko-health-scanner-us-push